Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus

References

• Stanley JR. Pemphigus and pemphigoid asparadigms of organ-specific autoantibody-mediated diseases. J.Clin.Invest. 1989;83:1443–1448.
   PubMed Web of Science ®Google Scholar
• Hebert V, Joly P. Rituximab in pemphigus. Immunotherapy. 2018;10:27–37.
   PubMed Web of Science ®Google Scholar
• Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869–877.
   PubMed Web of Science ®Google Scholar
• Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47:785–788.
   PubMed Web of Science ®Google Scholar
• Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
   PubMedGoogle Scholar
• Matsukura S, Knowles SR, Walsh S, et al. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol. 2012;148:734–739.
   PubMedGoogle Scholar
• Diab M, Bechtel M, Coloe J, et al. Treatment of refractory pemphigus erythematosus with rituximab. Int J Dermatol. 2008;47:1317–1318.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47:292–294.
   PubMed Web of Science ®Google Scholar
• Fernando SL, O’Connor KS. Treatment of severe pemphigus foliaceus with rituximab. Med J Aust. 2008;189:289–290.
   PubMed Web of Science ®Google Scholar
• Serrao VV, Martins A, Paris FR, et al. Successful treatment of recalcitrant pemphigus foliaceus with rituximab. J Eur Acad Dermatol Venereol. 2008;22:768–770.
   PubMed Web of Science ®Google Scholar
• Sorce M, Aricò M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther. 2008;21(Suppl. 1):S6–S9.
   PubMedGoogle Scholar
• Goh MSY, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156:990–996.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Fanoni D, Venegoni L, et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatol Basel Switz. 2007;214:310–318.
   PubMed Web of Science ®Google Scholar
• Arin MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620–625.
   PubMed Web of Science ®Google Scholar
• Dupuy A, Viguier M, B’Edane C. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91–96.
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82:575–585.e1.
   PubMed Web of Science ®Google Scholar
• Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913.
   PubMed Web of Science ®Google Scholar
• Reguiai Z, Tabary T, Maizières M, et al. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67(4):623–629. Oct
   PubMed Web of Science ®Google Scholar
• Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–622.
   PubMed Web of Science ®Google Scholar
• Currimbhoy S, Zhu V, Dominguez AR, et al. Rituximab in the treatment of 38 patients with Pemphigus with long-term follow-up. J Eur Acad Dermatol Venereol. 2016;30(6):1050–1052. Jun
   PubMed Web of Science ®Google Scholar
• Vinay K, Cazzaniga S, Amber KT, et al. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–808.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Gupta V, Bhari N, et al. Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up. Int J Dermatol. 2020;59(1):76–81.
   PubMed Web of Science ®Google Scholar
• De D, Bishnoi A, Handa S, et al. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: a retrospective single-center review of up to 68 months follow-up. Indian J Dermatol Venereol Leprol. 2020;86(1):39–44.
   PubMed Web of Science ®Google Scholar
• Shimanovich I, Baumann T, Schmidt E, et al. Long-term outcomes of rituximab therapy in pemphigus. J Eur Acad Dermatol Venereol. 2020;34(12):2884–2889.
   PubMed Web of Science ®Google Scholar
• Kim TH, Choi Y, Lee SE, et al. Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up. J Dermatol. 2017;44(6):615–620.
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138.
   PubMed Web of Science ®Google Scholar
• Uzun S, Bilgiç Temel A, Akman Karakaş A, et al. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Int J Dermatol. 2016;55:1362–1368.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points,and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
   PubMed Web of Science ®Google Scholar
• Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150(7):703–708.
   PubMed Web of Science ®Google Scholar
• Kushner CJ, Wang S, Tovanabutra N, et al. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404–1409.
   PubMed Web of Science ®Google Scholar
• Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venerol. 2015;95(8):928–932.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann NY Acad Sci. 2009;1173:683–691.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14:323–331.
   PubMed Web of Science ®Google Scholar
• Albers LN, Liu Y, Bo N, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–1082.
   PubMed Web of Science ®Google Scholar
• Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128(12):2859–2869.
   PubMed Web of Science ®Google Scholar
• Balighi K, Sakhi RS, Daneshpazhooh M, et al. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. 2018;31(6):e12671.
   PubMed Web of Science ®Google Scholar
• Mignard C, Maho-Vaillant M, Golinski ML, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(5):545–552.
   PubMed Web of Science ®Google Scholar
• Rashid H, Lamberts A, van Maanen D, et al. The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: Daily practice data from a retrospective study. J Am Acad Dermatol. 2020;83(5):1503–1505.
   PubMed Web of Science ®Google Scholar
• Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–325.
   PubMed Web of Science ®Google Scholar
• Horvath B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–412.
   PubMed Web of Science ®Google Scholar
• Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: protocol and single-centre long-term review of nine patients. Australas J Dermatol. 2018;59(1):E47–E52.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341–1349.
   PubMed Web of Science ®Google Scholar
• Russo I, Miotto S, Saponeri A, et al. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opin Biol Ther. 2020;20(6):673–678.
   PubMed Web of Science ®Google Scholar
• Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. Sci Rep. 2018;8(1):124.
   PubMedGoogle Scholar
• Baum S, Gilboa S, Greenberger S, et al. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases. J Dermatolog Treat. 2013;24:427–430.
   PubMed Web of Science ®Google Scholar
• Antonucci A, Negosanti M, Tabanelli M, et al. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog Treat. 2007;18:178–183.
   PubMed Web of Science ®Google Scholar
• Weger W, Aberer E. Treatment failure with rituximab in a patient with pemphigus vulgaris. J Eur Acad Dermatol Venerol. 2008;22(3):387–389.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Hennig K, Mengede C, et al. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009;132(3):334–341.
   PubMed Web of Science ®Google Scholar
• Gregoriou S, Giatrakou S, Theodoropoulos K, et al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology. 2014;228(2):158–165.
   PubMed Web of Science ®Google Scholar
• Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6:366–373.
   PubMed Web of Science ®Google Scholar
• Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79:97–103.
   PubMed Web of Science ®Google Scholar
• Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol. 2012;166:511–517.
   PubMed Web of Science ®Google Scholar
• Ujiie I, Ujiie H, Iwata H, et al. Clinical and immunological features of pemphigus relapse. Br J Dermatol. 2018;180:1498–1505.
   Google Scholar
• Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145(5):529–535.
   PubMedGoogle Scholar
• Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(9):1089–1103. Sep
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794.
   PubMedGoogle Scholar
• Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503–508.
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56:3896–3908.
   PubMed Web of Science ®Google Scholar